Management of unstable angina based on considerations of aetiology

Heart

Volumn 82, Issue SUPPL. 1, 1999, Pages

  Braunwald, E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; MACROLIDE; NITRATE; VASODILATOR AGENT;

ARTERY OCCLUSION; CORONARY ARTERY BYPASS GRAFT; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VASOCONSTRICTION; VASOSPASM;

EID: 0032841943     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.82.2008.i5     Document Type: Review

References (16)

1. Braunwald E. Unstable angina: a classification. Circulation 1989;80:410-14.
2. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin-I levels to predict risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
3. Maseri A. Pathogenic mechanisms in unstable angina. Heart 1999;82(suppl I):12-4.
4. Braunwald E. Unstable angina: an etiologic approach to management. Circulation 1998;98:2219-22.
5. Cohen M, Demers C, Gurfinkel EP for the ESSENCE Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 1997;337:447-52.
6. Antman E, Braunwald E, McCabe CH, et al. Enoxaparin for the acute and chronic management of unstable angina: results of the TIMI IIB trial. Circulation 1998;98:1-504.
7. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997:336;1689-96.
8. CAPTURE Investigators. Randomised placebo-controlled trial of abeiximab before and during coronary intervention in refractory angina: the CAPTURE study. Lancet 1997; 349:1429-34.
9. Platelet Receptor Inhibition for Ischaemic Syndrome Management in Patient Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
10. Kaski JC, Chester MR, Chen L, et al. Rapid angiographic progression of coronary artery disease in patients with angina pectoris: the role of complex stenosis morphology. Circulation 1995;92:2058-65.
11. Liuzzo G, Biasucci LM, Gallimore R, et al. The prognostic value of C-reactive protein and serum amyloid-A in severe unstable angina. N Engl J Med 1997;331:417-24.
12. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently and in combination with troponin-T in acute coronary syndromes. J Am Coll Cardiol 1998;31:1460-5.
13. Kuo CC, Gown AM, Benditt EP, et al. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993; 13:1501-4.
14. Gurfinkel E, Bozovich G, Daroca A, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. ROXIS Study Group. Lancet 1997;350: 404-7.
15. Gupta S, Leatham EW, Carrington E, et al. Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of acute myocardial infarction. Circulation 1997;96:404-7.
16. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of the coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-8.